Allakos


Allakos is a clinical-stage company developing antibodies that target receptor molecules present on the surface of immune effector cells involved in allergy, inflammation and tissue damage.

These antibodies directly inhibit or deplete mast cells and eosinophils, important effector cells in a broad spectrum of allergic and inflammatory conditions and several rare proliferative diseases.



  • Direct effect on mast cells and eosinophils may provide more potent activity than alternative approaches that target cytokines or IgE

  • Provides first-in-class therapeutics for multiple indications where mast cells and eosinophils contribute to disease

Read More


Allakos Management


Christopher Bebbington

Chris Bebbington
President and Chief Executive Officer

Alejandro Dorenbaum

Alejandro Dorenbaum
Chief Medical Officer

Simon Greenwood

Simon Greenwood
Chief Business Officer

Nenad Tomasevic

Nenad Tomasevic
VP Research

Sally Bolmer

Sally Bolmer
VP Regulatory Affairs and Drug Development

Omer Siddiqui

Omer Siddiqui
VP Clinical Operations